BioCentury
ARTICLE | Clinical News

ON 01910: Phase I/II data

December 21, 2009 8:00 AM UTC

Data from a dose-escalation Phase I/II trial in 13 evaluable patients showed that a weekly 48-hour continuous IV infusion of ON 01910.Na for 3 weeks of a 4-week cycle was well tolerated at doses of 80...